US20030125775A1 - Ventricular pacing for prevention of atrial fibrillation - Google Patents

Ventricular pacing for prevention of atrial fibrillation Download PDF

Info

Publication number
US20030125775A1
US20030125775A1 US10/038,498 US3849802A US2003125775A1 US 20030125775 A1 US20030125775 A1 US 20030125775A1 US 3849802 A US3849802 A US 3849802A US 2003125775 A1 US2003125775 A1 US 2003125775A1
Authority
US
United States
Prior art keywords
atrial
interval
ventricular
pace
pacing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/038,498
Other versions
US6957104B2 (en
Inventor
Darrell Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiac Pacemakers Inc
Original Assignee
Cardiac Pacemakers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers Inc filed Critical Cardiac Pacemakers Inc
Priority to US10/038,498 priority Critical patent/US6957104B2/en
Assigned to CARDIAC PACEMAKERS, INC. reassignment CARDIAC PACEMAKERS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WAGNER, DARRELL O.
Publication of US20030125775A1 publication Critical patent/US20030125775A1/en
Application granted granted Critical
Publication of US6957104B2 publication Critical patent/US6957104B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39Heart defibrillators
    • A61N1/3956Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3621Heart stimulators for treating or preventing abnormally high heart rate
    • A61N1/3622Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39Heart defibrillators
    • A61N1/395Heart defibrillators for treating atrial fibrillation

Definitions

  • This invention pertains to systems and methods for cardiac rhythm management.
  • the invention relates to cardiac pacemakers and their methods of operation.
  • Tachyarrhythmias are abnormal heart rhythms characterized by a rapid heart rate, typically expressed in units of beats per minute (bpm). They can occur in either chamber of the heart (i.e., ventricles or atria) or both. Examples of tachyarrhythmias include sinus tachycardia, ventricular tachycardia, ventricular fibrillation (VF), atrial tachycardia, and atrial fibrillation (AF). Tachycardia is characterized by a rapid rate, either due to an ectopic excitatory focus or abnormal excitation by normal pacemaker tissue, while fibrillation occurs when the chamber depolarizes in a chaotic fashion with abnormal depolarization waveforms as reflected by an EKG.
  • An electrical shock applied to a heart chamber can be used to terminate most tachyarrhythmias by depolarizing excitable myocardium, which thereby prolongs refractoriness, interrupts reentrant circuits, and discharges excitatory foci.
  • Implantable cardioverter/defibrillators provide this kind of therapy by delivering a shock pulse to the heart when fibrillation is detected by the device.
  • ICDs can be designed to treat either atrial or ventricular tachyarrhythmias, or both, and may also incorporate cardiac pacing functionality.
  • the most dangerous tachyarrhythmias are ventricular tachycardia and ventricular fibrillation, and ICDs have most commonly been applied in the treatment of those conditions.
  • ICDs are also capable, however, of detecting atrial tachyarrhythmias, such as atrial fibrillation and atrial flutter, and delivering a shock pulse to the atria in order to terminate the arrhythmia.
  • atrial fibrillation is associated with a loss of atrio-ventricular synchrony which can be hemodynamically compromising and cause such symptoms as dyspnea, fatigue, vertigo, and angina.
  • Atrial fibrillation can also predispose to strokes resulting from emboli forming in the left atrium.
  • ICDs configured to treat atrial fibrillation offer a number of advantages to certain patients, including convenience and greater efficacy. It would be even more beneficial if an implantable device could deliver electro-stimulatory therapy in a manner that would prevent the occurrence of atrial fibrillation.
  • Atrial fibrillation may be caused by the ventricular depolarization following a premature atrial contraction.
  • the ventricular depolarization in this situation stimulates the atrium during its vulnerable period, thus triggering the arrhythmia.
  • This type of atrial fibrillation can be prevented by pacing the ventricles at an instant following a premature atrial contraction that is either before or after the atrial vulnerable period.
  • Such ventricular pacing therapy for prevention of atrial fibrillation may be implemented in a patient either alone or in conjunction with other pacing therapy.
  • FIG. 1 is a system diagram of a pacemaker.
  • FIGS. 2A and 2B illustrate the steps involved in exemplary implementations.
  • Premature atrial contractions are atrial contractions resulting from ectopic excitatory foci in the atria that occur prior to the time they would normally be expected.
  • Such premature excitation of the atria spreads to the atrio-ventricular (AV) node and may or may not be conducted to the ventricles depending upon whether the AV node is still refractory from the preceding beat.
  • Ectopic foci can be due to local areas of ischemia, but premature atrial contractions can also occur in normal persons when provoked by drugs, alcohol, caffeine, or tobacco.
  • the atria are normally activated by an excitatory impulse originating in the SA node which then spreads throughout the atria and to the AV node, where it is then conducted by the His bundles and Purkinje fibers to activate the ventricles.
  • a PAC occurs, the excitation spreads from the ectopic site to the AV node so that the ectopic site in the atrium is depolarized sooner relative to the time of the subsequent ventricular depolarization than is normally the case.
  • the atrial ectopic site also repolarizes sooner as well, so that its vulnerable period may coincide with the ventricular depolarization. If the ventricular depolarization is conducted retrogradely back to the atria during the vulnerable period, atrial fibrillation may be triggered.
  • the mechanical stresses induced in the atria by ventricular contraction may also be responsible for triggering atrial fibrillation.
  • Ventricular pacing may be employed to prevent the type of atrial fibrillation described above by pacing the ventricles while the atria are not in a vulnerable period after a PAC is detected.
  • One way of detecting PACs is to measure the interval between successive atrial senses, referred to as the A-A interval, and declare an atrial sense to be a PAC if the current A-A interval is less than a specified percentage of the preceding A-A interval or some average of preceding A-A intervals.
  • a ventricular pace may then be delivered at an AV delay interval shorter than the intrinsic AV conduction time so that the ventricular depolarization occurs earlier with respect to the PAC than would naturally occur and before the most vulnerable period of the atrium.
  • the timing of the ventricular pace may also be constrained by a minimum interval from the previous ventricular sense or pace so as to avoid pacing the ventricle during its vulnerable period.
  • a different method of ventricular pacing after a PAC may be used.
  • Patients with an AV block may be treated with an implantable pacemaker operating in a bradycardia pacing mode.
  • a ventricular pace is triggered after a programmed AV delay interval following an atrial sense to thus simulate an intact AV conduction pathway.
  • the programmed AV interval is normally set at a value that produces optimum hemodynamic performance.
  • the pacemaker may therefore be configured to undergo a mode switch upon detection of a PAC that lengthens the programmed AV delay interval. The ventricular pace is then delayed so that the ventricular depolarization occurs after the most vulnerable period of the atrium.
  • pacing may be the sole pacing therapy given to the patient, or it may be delivered in combination with a bradycardia pacing mode.
  • Cardiac rhythm management devices are implantable devices that provide electrical stimulation to selected chambers of the heart in order to treat disorders of cardiac rhythm and include pacemakers and implantable cardioverter/defibrillators.
  • a pacemaker is a cardiac rhythm management device that paces the heart with timed pacing pulses.
  • the term “pacemaker” as used herein should be taken to mean any device with a pacing functionality, such as an implantable cardioverter/defibrillator with a pacemaker incorporated therein.
  • a microprocessor-based cardiac rhythm management device will be referred to as incorporating the system and method that is the present invention.
  • the invention is implemented with a control unit made up of a microprocessor executing programmed instructions in memory.
  • control unit made up of a microprocessor executing programmed instructions in memory.
  • certain functions of a cardiac rhythm management device could be controlled by custom logic circuitry either in addition to or instead of a programmed microprocessor.
  • the terms “controller” or “circuitry” as used herein should therefore be taken to encompass either custom circuitry (i.e., dedicated hardware) or a microprocessor executing programmed instructions contained in a processor-readable storage medium along with associated circuit elements.
  • Implantable cardiac rhythm management devices such as pacemakers and ICD's, are electronic devices that are implanted subcutaneously on a patient's chest with leads threaded intravenously into the heart to connect the device to electrodes used for sensing electrical activity and for electrical stimulation of the heart.
  • FIG. 1 is a system diagram of a microprocessor-based cardiac rhythm management device with the capability of delivering cardioversion/defibrillation shocks as well as antitachycardia pacing (ATP) therapy.
  • the device may also be configured to deliver conventional (e.g., bradycardia) pacing as well.
  • the controller 10 of the pacemaker is a microprocessor that communicates with a memory 12 via a bidirectional data bus.
  • the memory 12 typically comprises a ROM (read-only memory) for program storage and a RAM (random-access memory) for data storage.
  • the pacemaker has atrial and ventricular sensing/pacing channels that respectively include electrodes 24 and 34 , leads 23 and 33 , sensing amplifiers 21 and 31 , pulse generators 22 and 32 , and channel interfaces 20 and 30 . Incorporated into each sensing/pacing channel is thus a pacing channel made up of the pulse generator connected to the electrode and a sensing channel made up of the sense amplifier connected to the electrode. In this embodiment, a single electrode is used for sensing and pacing in each channel, known as a unipolar lead.
  • bipolar leads that include two electrodes for outputting a pacing pulse and/or sensing intrinsic activity.
  • the channel interfaces communicate bidirectionally with microprocessor 10 and include analog-to-digital converters for digitizing sensing signal inputs from the sense amplifiers and registers that can be written to by the microprocessor in order to adjust the gain and threshold values for the sensing amplifiers, output pacing pulses, and change the pacing pulse amplitude and/or duration.
  • a telemetry interface 40 is also provided for communicating with an external programmer 500 that has an associated display 510 .
  • the controller 10 controls the overall operation of the device in accordance with programmed instructions stored in memory, including controlling the delivery of paces via the pacing channels, interpreting sense signals received from the sensing channels, and implementing timers for defining escape intervals and sensory refractory periods.
  • the sensing circuitry of the pacemaker detects a chamber sense when an electrogram signal (i.e., a voltage sensed by an electrode representing cardiac electrical activity) generated by a particular channel exceeds a specified detection threshold.
  • a chamber sense may be either an atrial sense or a ventricular sense depending on whether it occurs in the atrial or ventricular sensing channel.
  • Pacing algorithms used in particular pacing modes employ such senses to trigger or inhibit pacing.
  • the controller is also able to detect PACs such as by the method described above.
  • bradycardia The most common condition for which pacemakers are used is the treatment of bradycardia where the intrinsic heart rate is too slow.
  • the two most common causes of ventricular bradycardia are AV block and sick sinus syndrome.
  • Permanent pacing for bradycardia is indicated in patients with symptomatic bradycardia of any type as long as it is likely to be permanent or recurrent and is not associated with a transient condition from which the patient may recover.
  • Bradycardia pacing modes refer to pacing algorithms used to pace the atria and/or ventricles when the intrinsic atrial and/or ventricular rate is inadequate due to, for example, AV conduction blocks or sinus node dysfunction.
  • Such modes may either be single-chamber pacing, where either an atrium or a ventricle is paced, or dual-chamber pacing in which both an atrium and a ventricle are paced.
  • the modes are generally designated by a letter code of three positions where each letter in the code refers to a specific function of the pacemaker.
  • the first letter refers to which heart chambers are paced and which may be an A (for atrium), a V (for ventricle), D (for both chambers), or O (for none).
  • the second letter refers to which chambers are sensed by the pacemaker's sensing channels and uses the same letter designations as used for pacing.
  • the third letter refers to the pacemaker's response to a sensed P wave from the atrium or an R wave from the ventricle and may be an I (for inhibited), T (for triggered), D (for dual in which both triggering and inhibition are used), and O (for no response).
  • Modem pacemakers are typically programmable so that they can operate in any mode which the physical configuration of the device will allow. Additional sensing of physiological data allows some pacemakers to change the rate at which they pace the heart in accordance with some parameter correlated to metabolic demand. Such pacemakers are called rate-adaptive pacemakers and are designated by a fourth letter added to the three-letter code, R.
  • Pacemakers can enforce a minimum heart rate either asynchronously or synchronously.
  • asynchronous pacing the heart is paced at a fixed rate irrespective of intrinsic cardiac activity.
  • a pacing pulse will be delivered coincident with an intrinsic beat and during the heart's vulnerable period which may cause fibrillation.
  • Most pacemakers for treating bradycardia today are therefore programmed to operate synchronously in a so-called demand mode where sensed cardiac events occurring within a defined interval either trigger or inhibit a pacing pulse.
  • Inhibited demand pacing modes utilize escape intervals to control pacing in accordance with sensed intrinsic activity.
  • a pacing pulse is delivered to a heart chamber during a cardiac cycle only after expiration of a defined escape interval during which no intrinsic beat by the chamber is detected. If an intrinsic beat occurs during this interval, the heart is thus allowed to “escape” from pacing by the pacemaker.
  • a defined escape interval can be defined for each paced chamber.
  • a ventricular escape interval can be defined between ventricular events so as to be restarted with each ventricular sense or pace. The inverse of this escape interval is the minimum rate at which the pacemaker will allow the ventricles to beat, sometimes referred to as the lower rate limit (LRL).
  • atrio-ventricular interval In atrial tracking pacemakers (i.e., VDD or DDD mode), another ventricular escape interval is defined between atrial and ventricular events, referred to as the atrio-ventricular interval (or AV interval).
  • the atrio-ventricular interval is triggered by an atrial sense or pace and stopped by a ventricular sense or pace.
  • a ventricular pace is delivered upon expiration of the atrio-ventricular interval if no ventricular sense occurs before.
  • Atrial-tracking ventricular pacing attempts to maintain the atrio-ventricular synchrony occurring with physiological beats whereby atrial contractions augment diastolic filling of the ventricles.
  • Atrial triggered modes such as DDD or VDD are desirable because they allow the pacing to track the physiologically normal atrial rhythm, which causes cardiac output to be responsive to the metabolic needs of the body.
  • a pacemaker can also be configured to pace the atria on an inhibited demand basis.
  • An atrial escape interval is then defined as the maximum time interval in which an atrial sense must be detected after a ventricular sense or pace before an atrial pace will be delivered.
  • atrial inhibited demand pacing is combined with atrial-triggered ventricular demand pacing (i.e., DDD mode)
  • both the atria and ventricles are paced in the absence of intrinsic activity, termed AV sequential pacing.
  • the lower rate limit interval is then the sum of the atrial escape interval and the atrio-ventricular interval.
  • Cardiac resynchronization therapy is pacing stimulation applied to one or more heart chambers in a manner that restores or maintains synchronized contractions of the atria and/or ventricles and thereby improves pumping efficiency.
  • One way to deliver resynchronization therapy is to pace a site with a synchronous bradycardia pacing mode and then deliver one or more resynchronization paces to one or more additional pacing sites in a defined time relation to one or more selected sensing or pacing events that either reset escape intervals or trigger paces in the bradycardia pacing mode.
  • Ventricular pacing after PAC detection in order to prevent atrial fibrillation may be implemented in conjunction with any of the bradycardia pacing modes discussed above. As described below, however, the implementation may be slightly different depending upon whether the mode is an atrial tracking or non-atrial tracking mode.
  • FIG. 2A illustrates an exemplary scheme by which the device in FIG. 1 may be configured to deliver ventricular pacing for preventing atrial fibrillation either when no other pacing therapy is being delivered or in combination with a non-atrial tracking bradycardia pacing mode.
  • Step A 1 represents the normal bradycardia pacing mode that the device uses to deliver pacing when no PAC has been detected.
  • the device measures successive A-A intervals and compares each such interval with the criteria for declaring a PAC.
  • the device If no PAC is detected, the device returns to the bradycardia pacing mode at step A 1 or, in the case where no bradycardia pacing is being delivered, returns to monitoring A-A intervals at step A 2 .
  • the device delivers a ventricular pace at step A 3 at a specified AV interval selected to be either: 1) an early-pace AV interval that is less than the intrinsic AV conduction time and results in a ventricular pace before the atrium's vulnerable period, or 2) a late-pace AV interval that results in a ventricular pace after the atrium's vulnerable period.
  • the value of the early-pace AV interval may be specified by the clinician and set using an external programmer, or may be set automatically by the device as a percentage of the intrinsic AV conduction time measured from electrogram signals during an intrinsic heartbeat.
  • the device may constrain the AV interval so that the ventricular pace is delivered after a specified minimum interval from the previous ventricular sense or pace in order to avoid pacing the ventricle during its vulnerable period.
  • the late-pace AV interval can be used when the patent has a complete AV block so that no physiological conduction from the atria to the ventricles occurs.
  • the late-pace AV interval results in the ventricular pace being delivered after the vulnerable period of the atrium has passed.
  • the value of the late-pace AV interval can be determined by a clinician from electrophysiological measurements and set using an external programmer. After the ventricular pace is delivered, the device returns to the bradycardia pacing mode at step A 1 and/or monitoring A-A intervals at step A 2 .
  • FIG. 2B illustrates an alternative scheme for delivering ventricular pacing to prevent atrial fibrillation in conjunction with an atrial tracking bradycardia pacing mode (i.e., either DDD or VDD).
  • an atrial tracking bradycardia pacing mode i.e., either DDD or VDD.
  • a mode normally employs a programmed AV interval to deliver a ventricular pace after an atrial sense.
  • Ventricular pacing after a PAC is detected can thus be implemented as a mode switch in which the AV interval is modified to be either a late-pace AV interval or an early-pace AV as described above.
  • Step B 1 represents the normal bradycardia pacing mode with atrial tracking, which may also include AV sequential pacing (i.e., DDD mode).
  • step B 2 successive A-A intervals are measured and compared with the criteria for declaring a PAC. If a PAC is detected, the AV interval is adjusted at step B 3 to either a late-pace AV interval or an early-pace AV interval as described above. The device then returns to the bradycardia mode at step B 1 which carries out the ventricular pacing using the adjusted AV interval. The next A-A interval is then measured and, if no PAC is detected, the AV interval is set to its normal programmed value at step B 4 , and bradycardia pacing is resumed at step B 1 .

Abstract

A method and apparatus for preventing atrial fibrillation arising from a premature atrial contraction. Upon detection of a premature atrial contraction, a pace is delivered to a ventricle at a specified AV interval selected as either a late-pace or early-pace value. The resulting ventricular depolarization then occurs during a time when the atria are not vulnerable to the triggering of fibrillation.

Description

    FIELD OF THE INVENTION
  • This invention pertains to systems and methods for cardiac rhythm management. In particular, the invention relates to cardiac pacemakers and their methods of operation. [0001]
  • BACKGROUND
  • Tachyarrhythmias are abnormal heart rhythms characterized by a rapid heart rate, typically expressed in units of beats per minute (bpm). They can occur in either chamber of the heart (i.e., ventricles or atria) or both. Examples of tachyarrhythmias include sinus tachycardia, ventricular tachycardia, ventricular fibrillation (VF), atrial tachycardia, and atrial fibrillation (AF). Tachycardia is characterized by a rapid rate, either due to an ectopic excitatory focus or abnormal excitation by normal pacemaker tissue, while fibrillation occurs when the chamber depolarizes in a chaotic fashion with abnormal depolarization waveforms as reflected by an EKG. [0002]
  • An electrical shock applied to a heart chamber (i.e., defibrillation or cardioversion) can be used to terminate most tachyarrhythmias by depolarizing excitable myocardium, which thereby prolongs refractoriness, interrupts reentrant circuits, and discharges excitatory foci. Implantable cardioverter/defibrillators (ICDs) provide this kind of therapy by delivering a shock pulse to the heart when fibrillation is detected by the device. ICDs can be designed to treat either atrial or ventricular tachyarrhythmias, or both, and may also incorporate cardiac pacing functionality. The most dangerous tachyarrhythmias are ventricular tachycardia and ventricular fibrillation, and ICDs have most commonly been applied in the treatment of those conditions. [0003]
  • ICDs are also capable, however, of detecting atrial tachyarrhythmias, such as atrial fibrillation and atrial flutter, and delivering a shock pulse to the atria in order to terminate the arrhythmia. Although not immediately life threatening, it is important to treat atrial fibrillation for several reasons. First, atrial fibrillation is associated with a loss of atrio-ventricular synchrony which can be hemodynamically compromising and cause such symptoms as dyspnea, fatigue, vertigo, and angina. Atrial fibrillation can also predispose to strokes resulting from emboli forming in the left atrium. Although drug therapy and/or in-hospital cardioversion are acceptable treatment modalities for atrial fibrillation, ICDs configured to treat atrial fibrillation offer a number of advantages to certain patients, including convenience and greater efficacy. It would be even more beneficial if an implantable device could deliver electro-stimulatory therapy in a manner that would prevent the occurrence of atrial fibrillation. [0004]
  • SUMMARY OF THE INVENTION
  • Certain episodes of atrial fibrillation may be caused by the ventricular depolarization following a premature atrial contraction. The ventricular depolarization in this situation stimulates the atrium during its vulnerable period, thus triggering the arrhythmia. This type of atrial fibrillation can be prevented by pacing the ventricles at an instant following a premature atrial contraction that is either before or after the atrial vulnerable period. Such ventricular pacing therapy for prevention of atrial fibrillation may be implemented in a patient either alone or in conjunction with other pacing therapy. [0005]
  • This description is intended to provide an overview of the subject matter of the present patent application and is not an exhaustive or exclusive explanation of the invention.[0006]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a system diagram of a pacemaker. [0007]
  • FIGS. 2A and 2B illustrate the steps involved in exemplary implementations.[0008]
  • DETAILED DESCRIPTION
  • Premature atrial contractions (PACs) are atrial contractions resulting from ectopic excitatory foci in the atria that occur prior to the time they would normally be expected. Such premature excitation of the atria spreads to the atrio-ventricular (AV) node and may or may not be conducted to the ventricles depending upon whether the AV node is still refractory from the preceding beat. Ectopic foci can be due to local areas of ischemia, but premature atrial contractions can also occur in normal persons when provoked by drugs, alcohol, caffeine, or tobacco. [0009]
  • The atria are normally activated by an excitatory impulse originating in the SA node which then spreads throughout the atria and to the AV node, where it is then conducted by the His bundles and Purkinje fibers to activate the ventricles. When a PAC occurs, the excitation spreads from the ectopic site to the AV node so that the ectopic site in the atrium is depolarized sooner relative to the time of the subsequent ventricular depolarization than is normally the case. This means that the atrial ectopic site also repolarizes sooner as well, so that its vulnerable period may coincide with the ventricular depolarization. If the ventricular depolarization is conducted retrogradely back to the atria during the vulnerable period, atrial fibrillation may be triggered. The mechanical stresses induced in the atria by ventricular contraction may also be responsible for triggering atrial fibrillation. [0010]
  • Ventricular pacing may be employed to prevent the type of atrial fibrillation described above by pacing the ventricles while the atria are not in a vulnerable period after a PAC is detected. One way of detecting PACs is to measure the interval between successive atrial senses, referred to as the A-A interval, and declare an atrial sense to be a PAC if the current A-A interval is less than a specified percentage of the preceding A-A interval or some average of preceding A-A intervals. Upon detection of a PAC, a ventricular pace may then be delivered at an AV delay interval shorter than the intrinsic AV conduction time so that the ventricular depolarization occurs earlier with respect to the PAC than would naturally occur and before the most vulnerable period of the atrium. The timing of the ventricular pace may also be constrained by a minimum interval from the previous ventricular sense or pace so as to avoid pacing the ventricle during its vulnerable period. [0011]
  • If a patient suffers from an AV block so that either the intrinsic AV conduction time is abnormally long or no AV conduction pathway exists, a different method of ventricular pacing after a PAC may be used. Patients with an AV block may be treated with an implantable pacemaker operating in a bradycardia pacing mode. In a DDD or VDD mode, for example, a ventricular pace is triggered after a programmed AV delay interval following an atrial sense to thus simulate an intact AV conduction pathway. The programmed AV interval is normally set at a value that produces optimum hemodynamic performance. When a PAC occurs, however, and if a ventricular pace is delivered at the normal programmed AV interval, the ventricles may depolarize during the atrial vulnerable period. The pacemaker may therefore be configured to undergo a mode switch upon detection of a PAC that lengthens the programmed AV delay interval. The ventricular pace is then delayed so that the ventricular depolarization occurs after the most vulnerable period of the atrium. [0012]
  • Described below is an exemplary device for carrying out ventricular pacing in order to prevent the triggering of atrial fibrillation by a PAC. Such pacing may be the sole pacing therapy given to the patient, or it may be delivered in combination with a bradycardia pacing mode. [0013]
  • 1. Hardware Platform [0014]
  • Cardiac rhythm management devices are implantable devices that provide electrical stimulation to selected chambers of the heart in order to treat disorders of cardiac rhythm and include pacemakers and implantable cardioverter/defibrillators. A pacemaker is a cardiac rhythm management device that paces the heart with timed pacing pulses. The term “pacemaker” as used herein should be taken to mean any device with a pacing functionality, such as an implantable cardioverter/defibrillator with a pacemaker incorporated therein. [0015]
  • In the description that follows, a microprocessor-based cardiac rhythm management device will be referred to as incorporating the system and method that is the present invention. In the embodiment to be described, the invention is implemented with a control unit made up of a microprocessor executing programmed instructions in memory. It should be appreciated, however, that certain functions of a cardiac rhythm management device could be controlled by custom logic circuitry either in addition to or instead of a programmed microprocessor. The terms “controller” or “circuitry” as used herein should therefore be taken to encompass either custom circuitry (i.e., dedicated hardware) or a microprocessor executing programmed instructions contained in a processor-readable storage medium along with associated circuit elements. [0016]
  • Implantable cardiac rhythm management devices, such as pacemakers and ICD's, are electronic devices that are implanted subcutaneously on a patient's chest with leads threaded intravenously into the heart to connect the device to electrodes used for sensing electrical activity and for electrical stimulation of the heart. FIG. 1 is a system diagram of a microprocessor-based cardiac rhythm management device with the capability of delivering cardioversion/defibrillation shocks as well as antitachycardia pacing (ATP) therapy. The device may also be configured to deliver conventional (e.g., bradycardia) pacing as well. The [0017] controller 10 of the pacemaker is a microprocessor that communicates with a memory 12 via a bidirectional data bus. The memory 12 typically comprises a ROM (read-only memory) for program storage and a RAM (random-access memory) for data storage. The pacemaker has atrial and ventricular sensing/pacing channels that respectively include electrodes 24 and 34, leads 23 and 33, sensing amplifiers 21 and 31, pulse generators 22 and 32, and channel interfaces 20 and 30. Incorporated into each sensing/pacing channel is thus a pacing channel made up of the pulse generator connected to the electrode and a sensing channel made up of the sense amplifier connected to the electrode. In this embodiment, a single electrode is used for sensing and pacing in each channel, known as a unipolar lead. Other embodiments may employ bipolar leads that include two electrodes for outputting a pacing pulse and/or sensing intrinsic activity. The channel interfaces communicate bidirectionally with microprocessor 10 and include analog-to-digital converters for digitizing sensing signal inputs from the sense amplifiers and registers that can be written to by the microprocessor in order to adjust the gain and threshold values for the sensing amplifiers, output pacing pulses, and change the pacing pulse amplitude and/or duration. A telemetry interface 40 is also provided for communicating with an external programmer 500 that has an associated display 510.
  • The [0018] controller 10 controls the overall operation of the device in accordance with programmed instructions stored in memory, including controlling the delivery of paces via the pacing channels, interpreting sense signals received from the sensing channels, and implementing timers for defining escape intervals and sensory refractory periods. The sensing circuitry of the pacemaker detects a chamber sense when an electrogram signal (i.e., a voltage sensed by an electrode representing cardiac electrical activity) generated by a particular channel exceeds a specified detection threshold. A chamber sense may be either an atrial sense or a ventricular sense depending on whether it occurs in the atrial or ventricular sensing channel. Pacing algorithms used in particular pacing modes employ such senses to trigger or inhibit pacing. By measuring the interval between successive atrial senses, the controller is also able to detect PACs such as by the method described above.
  • 2. Bradycardia Pacing Modes [0019]
  • The most common condition for which pacemakers are used is the treatment of bradycardia where the intrinsic heart rate is too slow. The two most common causes of ventricular bradycardia are AV block and sick sinus syndrome. Permanent pacing for bradycardia is indicated in patients with symptomatic bradycardia of any type as long as it is likely to be permanent or recurrent and is not associated with a transient condition from which the patient may recover. Bradycardia pacing modes refer to pacing algorithms used to pace the atria and/or ventricles when the intrinsic atrial and/or ventricular rate is inadequate due to, for example, AV conduction blocks or sinus node dysfunction. Such modes may either be single-chamber pacing, where either an atrium or a ventricle is paced, or dual-chamber pacing in which both an atrium and a ventricle are paced. The modes are generally designated by a letter code of three positions where each letter in the code refers to a specific function of the pacemaker. The first letter refers to which heart chambers are paced and which may be an A (for atrium), a V (for ventricle), D (for both chambers), or O (for none). The second letter refers to which chambers are sensed by the pacemaker's sensing channels and uses the same letter designations as used for pacing. The third letter refers to the pacemaker's response to a sensed P wave from the atrium or an R wave from the ventricle and may be an I (for inhibited), T (for triggered), D (for dual in which both triggering and inhibition are used), and O (for no response). Modem pacemakers are typically programmable so that they can operate in any mode which the physical configuration of the device will allow. Additional sensing of physiological data allows some pacemakers to change the rate at which they pace the heart in accordance with some parameter correlated to metabolic demand. Such pacemakers are called rate-adaptive pacemakers and are designated by a fourth letter added to the three-letter code, R. [0020]
  • Pacemakers can enforce a minimum heart rate either asynchronously or synchronously. In asynchronous pacing, the heart is paced at a fixed rate irrespective of intrinsic cardiac activity. There is thus a risk with asynchronous pacing that a pacing pulse will be delivered coincident with an intrinsic beat and during the heart's vulnerable period which may cause fibrillation. Most pacemakers for treating bradycardia today are therefore programmed to operate synchronously in a so-called demand mode where sensed cardiac events occurring within a defined interval either trigger or inhibit a pacing pulse. Inhibited demand pacing modes utilize escape intervals to control pacing in accordance with sensed intrinsic activity. In an inhibited demand mode, a pacing pulse is delivered to a heart chamber during a cardiac cycle only after expiration of a defined escape interval during which no intrinsic beat by the chamber is detected. If an intrinsic beat occurs during this interval, the heart is thus allowed to “escape” from pacing by the pacemaker. Such an escape interval can be defined for each paced chamber. For example, a ventricular escape interval can be defined between ventricular events so as to be restarted with each ventricular sense or pace. The inverse of this escape interval is the minimum rate at which the pacemaker will allow the ventricles to beat, sometimes referred to as the lower rate limit (LRL). [0021]
  • In atrial tracking pacemakers (i.e., VDD or DDD mode), another ventricular escape interval is defined between atrial and ventricular events, referred to as the atrio-ventricular interval (or AV interval). The atrio-ventricular interval is triggered by an atrial sense or pace and stopped by a ventricular sense or pace. A ventricular pace is delivered upon expiration of the atrio-ventricular interval if no ventricular sense occurs before. Atrial-tracking ventricular pacing attempts to maintain the atrio-ventricular synchrony occurring with physiological beats whereby atrial contractions augment diastolic filling of the ventricles. In chronotropically competent patients (i.e., those patients whose atrial rhythm is responsive to metabolic demand) in need of ventricular pacing, atrial triggered modes such as DDD or VDD are desirable because they allow the pacing to track the physiologically normal atrial rhythm, which causes cardiac output to be responsive to the metabolic needs of the body. [0022]
  • A pacemaker can also be configured to pace the atria on an inhibited demand basis. An atrial escape interval is then defined as the maximum time interval in which an atrial sense must be detected after a ventricular sense or pace before an atrial pace will be delivered. When atrial inhibited demand pacing is combined with atrial-triggered ventricular demand pacing (i.e., DDD mode), both the atria and ventricles are paced in the absence of intrinsic activity, termed AV sequential pacing. The lower rate limit interval is then the sum of the atrial escape interval and the atrio-ventricular interval. [0023]
  • Cardiac resynchronization therapy is pacing stimulation applied to one or more heart chambers in a manner that restores or maintains synchronized contractions of the atria and/or ventricles and thereby improves pumping efficiency. One way to deliver resynchronization therapy is to pace a site with a synchronous bradycardia pacing mode and then deliver one or more resynchronization paces to one or more additional pacing sites in a defined time relation to one or more selected sensing or pacing events that either reset escape intervals or trigger paces in the bradycardia pacing mode. [0024]
  • Ventricular pacing after PAC detection in order to prevent atrial fibrillation may be implemented in conjunction with any of the bradycardia pacing modes discussed above. As described below, however, the implementation may be slightly different depending upon whether the mode is an atrial tracking or non-atrial tracking mode. [0025]
  • 3. AF Prevention Combined with Non-Atrial Tracking Bradycardia Mode [0026]
  • FIG. 2A illustrates an exemplary scheme by which the device in FIG. 1 may be configured to deliver ventricular pacing for preventing atrial fibrillation either when no other pacing therapy is being delivered or in combination with a non-atrial tracking bradycardia pacing mode. Step A[0027] 1 represents the normal bradycardia pacing mode that the device uses to deliver pacing when no PAC has been detected. At step A2, the device measures successive A-A intervals and compares each such interval with the criteria for declaring a PAC. If no PAC is detected, the device returns to the bradycardia pacing mode at step A1 or, in the case where no bradycardia pacing is being delivered, returns to monitoring A-A intervals at step A2. When a PAC is detected, the device delivers a ventricular pace at step A3 at a specified AV interval selected to be either: 1) an early-pace AV interval that is less than the intrinsic AV conduction time and results in a ventricular pace before the atrium's vulnerable period, or 2) a late-pace AV interval that results in a ventricular pace after the atrium's vulnerable period. The value of the early-pace AV interval may be specified by the clinician and set using an external programmer, or may be set automatically by the device as a percentage of the intrinsic AV conduction time measured from electrogram signals during an intrinsic heartbeat. When the early-pace AV interval is used, the device may constrain the AV interval so that the ventricular pace is delivered after a specified minimum interval from the previous ventricular sense or pace in order to avoid pacing the ventricle during its vulnerable period. The late-pace AV interval can be used when the patent has a complete AV block so that no physiological conduction from the atria to the ventricles occurs. The late-pace AV interval results in the ventricular pace being delivered after the vulnerable period of the atrium has passed. The value of the late-pace AV interval can be determined by a clinician from electrophysiological measurements and set using an external programmer. After the ventricular pace is delivered, the device returns to the bradycardia pacing mode at step A1 and/or monitoring A-A intervals at step A2.
  • 4. AF Prevention Combined with Atrial Tracking Bradycardia Mode [0028]
  • FIG. 2B illustrates an alternative scheme for delivering ventricular pacing to prevent atrial fibrillation in conjunction with an atrial tracking bradycardia pacing mode (i.e., either DDD or VDD). As described above, such a mode normally employs a programmed AV interval to deliver a ventricular pace after an atrial sense. Ventricular pacing after a PAC is detected can thus be implemented as a mode switch in which the AV interval is modified to be either a late-pace AV interval or an early-pace AV as described above. Step B[0029] 1 represents the normal bradycardia pacing mode with atrial tracking, which may also include AV sequential pacing (i.e., DDD mode). At step B2, successive A-A intervals are measured and compared with the criteria for declaring a PAC. If a PAC is detected, the AV interval is adjusted at step B3 to either a late-pace AV interval or an early-pace AV interval as described above. The device then returns to the bradycardia mode at step B1 which carries out the ventricular pacing using the adjusted AV interval. The next A-A interval is then measured and, if no PAC is detected, the AV interval is set to its normal programmed value at step B4, and bradycardia pacing is resumed at step B1.
  • Although the invention has been described in conjunction with the foregoing specific embodiment, many alternatives, variations, and modifications will be apparent to those of ordinary skill in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims. [0030]

Claims (20)

What is claimed is:
1. A cardiac rhythm management device, comprising:
an atrial sensing channel for generating atrial electrogram signals;
circuitry for detecting atrial senses when the atrial electrogram signal exceeds a specified threshold;
circuitry for measuring a time interval between successive atrial senses and for detecting a premature atrial contraction when the time interval meets a specified criterion;
a ventricular pacing channel for delivering pacing pulses to a ventricle; and,
circuitry for causing a ventricular pace to be delivered only when a premature atrial contraction is detected, wherein the ventricular pace is delivered at a specified AV interval following the premature atrial contraction.
2. The device of claim 1 further comprising circuitry for pacing one or more heart chambers in accordance with an atrial tracking bradycardia pacing mode when no premature atrial contraction has been detected.
3. The device of claim 1 wherein the specified AV interval is a late-pace value.
4. The device of claim 1 wherein the specified AV interval is an early-pace value.
5. The device of claim 4 wherein the AV interval is constrained so that the ventricular pace is delivered after a specified minimum interval from the previous ventricular sense or ventricular pace.
6. A cardiac rhythm management device, comprising:
an atrial sensing channel for generating atrial electrogram signals;
circuitry for detecting atrial senses when the atrial electrogram signal exceeds a specified threshold;
circuitry for measuring a time interval between successive atrial senses and for detecting a premature atrial contraction when the time interval meets a specified criterion;
a ventricular pacing channel for delivering pacing pulses to a ventricle;
circuitry for causing a ventricular pace to be delivered in accordance with an atrial tracking bradycardia pacing mode such that a ventricular pace is delivered at a specified AV interval following an atrial sense;
circuitry for modifying the AV interval when a premature atrial contraction is detected.
7. The device of claim 6 wherein the AV interval is modified to a late-pace value when a premature atrial contraction is detected.
8. The device of claim 6 wherein the AV interval is modified to an early-pace value when a premature atrial contraction is detected.
9. The device of claim 8 wherein the AV interval is constrained so that the ventricular pace is delivered after a specified minimum interval from the previous sensed or paced ventricular beat.
10. The device of claim 6 wherein the bradycardia pacing mode includes AV sequential pacing.
11. A method for operating a cardiac rhythm management device, comprising:
detecting an atrial sense when an atrial electrogram signal exceeds a specified threshold;
measuring a time interval between successive atrial senses and detecting a premature atrial contraction when the time interval meets a specified criterion;
delivering a pacing pulse to a ventricle when a premature atrial contraction is detected, wherein the ventricular pace is delivered at a specified AV interval following the premature atrial contraction.
12. The method of claim 11 further comprising pacing one or more heart chambers in accordance with a bradycardia pacing mode when no premature atrial contraction has been detected.
13. The method of claim 11 wherein the specified AV interval is a late-pace value.
14. The method of claim 11 wherein the specified AV interval is an early-pace value.
15. The method of claim 14 wherein the AV interval is constrained so that the ventricular pace is delivered after a specified minimum interval from the previous ventricular sense or ventricular pace.
16. A method for operating a cardiac rhythm management device, comprising:
detecting an atrial sense when an atrial electrogram signal exceeds a specified threshold;
measuring a time interval between successive atrial senses and detecting a premature atrial contraction when the time interval meets a specified criterion;
delivering pacing pulses to a ventricle in accordance with an atrial tracking bradycardia pacing mode such that a ventricular pace is delivered at a specified AV interval following an atrial sense; and, modifying the AV interval when a premature atrial contraction is detected.
17. The method of claim 16 wherein the AV interval is modified to a late-pace value when a premature atrial contraction is detected.
18. The method of claim 16 wherein the AV interval is modified to an early-pace value when a premature atrial contraction is detected.
19. The method of claim 18 wherein the AV interval is constrained so that the ventricular pace is delivered after a specified minimum interval from the previous sensed or paced ventricular beat.
20. The method of claim 16 wherein the bradycardia pacing mode includes AV sequential pacing.
US10/038,498 2002-01-03 2002-01-03 Ventricular pacing for prevention of atrial fibrillation Expired - Fee Related US6957104B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/038,498 US6957104B2 (en) 2002-01-03 2002-01-03 Ventricular pacing for prevention of atrial fibrillation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/038,498 US6957104B2 (en) 2002-01-03 2002-01-03 Ventricular pacing for prevention of atrial fibrillation

Publications (2)

Publication Number Publication Date
US20030125775A1 true US20030125775A1 (en) 2003-07-03
US6957104B2 US6957104B2 (en) 2005-10-18

Family

ID=21900297

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/038,498 Expired - Fee Related US6957104B2 (en) 2002-01-03 2002-01-03 Ventricular pacing for prevention of atrial fibrillation

Country Status (1)

Country Link
US (1) US6957104B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260409A (en) * 2018-12-06 2021-08-13 美敦力公司 Method and apparatus for establishing parameters for cardiac event detection
WO2023226600A1 (en) * 2022-05-26 2023-11-30 丹源医学科技(杭州)有限公司 Pacing device for preventing occurrence of atrial fibrillation following premature atrial contraction

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7668594B2 (en) * 2005-08-19 2010-02-23 Cardiac Pacemakers, Inc. Method and apparatus for delivering chronic and post-ischemia cardiac therapies
US7917210B2 (en) 2005-05-13 2011-03-29 Cardiac Pacemakers, Inc. Method and apparatus for cardiac protection pacing
US7894896B2 (en) 2005-05-13 2011-02-22 Cardiac Pacemakers, Inc. Method and apparatus for initiating and delivering cardiac protection pacing
US20060259088A1 (en) * 2005-05-13 2006-11-16 Pastore Joseph M Method and apparatus for delivering pacing pulses using a coronary stent
US7599738B2 (en) * 2005-05-17 2009-10-06 Cardiac Pacemakers, Inc. Synchronized ventricular pacing to promote atrial sensing
WO2009097118A1 (en) 2008-01-29 2009-08-06 Cardiac Pacemakers, Inc Configurable intermittent pacing therapy
US8483826B2 (en) 2008-03-17 2013-07-09 Cardiac Pacemakers, Inc. Deactivation of intermittent pacing therapy

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363325A (en) * 1981-01-19 1982-12-14 Medtronic, Inc. Mode adaptive pacer
US4412541A (en) * 1981-04-10 1983-11-01 Max Schaldach Cardiac pacemaker
US4452248A (en) * 1981-10-13 1984-06-05 Keller Jr J Walter Bidirectional pacemaker
US5042497A (en) * 1990-01-30 1991-08-27 Cardiac Pacemakers, Inc. Arrhythmia prediction and prevention for implanted devices
US5133350A (en) * 1991-01-31 1992-07-28 Medtronic, Inc. Mode switching pacemaker
US5247930A (en) * 1992-02-04 1993-09-28 Vitatron Medical, B.V. Dual chamber pacing system with dynamic physiological tracking and method of timing delivered stimulus for optimized synchronous pacing
US5340361A (en) * 1992-11-13 1994-08-23 Siemens Pacesetter, Inc. Implantable pacemaker having adaptive AV interval adoptively shortened to assure ventricular pacing
US5403356A (en) * 1993-04-28 1995-04-04 Medtronic, Inc. Method and apparatus for prevention of atrial tachy arrhythmias
US5514161A (en) * 1994-04-05 1996-05-07 Ela Medical S.A. Methods and apparatus for controlling atrial stimulation in a double atrial triple chamber cardiac pacemaker
US5674251A (en) * 1994-04-21 1997-10-07 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US5683429A (en) * 1996-04-30 1997-11-04 Medtronic, Inc. Method and apparatus for cardiac pacing to prevent atrial fibrillation
US5713929A (en) * 1996-05-03 1998-02-03 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using ratchet up and decay modes of operation
US5716383A (en) * 1996-02-28 1998-02-10 Medtronic, Inc. Dual chamber pacing system and method with continual adjustment of the AV escape interval so as to maintain optimized ventricular pacing for treating cardiomyopathy
US5782887A (en) * 1997-03-26 1998-07-21 Vitatron Medical, B.V. Pacemaker system with PAC tracking based on QT data
US5978709A (en) * 1998-06-16 1999-11-02 Vitatron Medical, B.V. Pacemaker system with improved techniques for preventing and suppressing atrial arrhythmias
US6122545A (en) * 1998-04-28 2000-09-19 Medtronic, Inc. Multiple channel sequential cardiac pacing method
US6292694B1 (en) * 1999-06-22 2001-09-18 Pacesetter, Inc. Implantable medical device having atrial tachyarrhythmia prevention therapy
US6330477B1 (en) * 1999-04-12 2001-12-11 Medtronic, Inc. Ventricular synchronized atrial pacing mode of implantable cardioverter/defibrillator
US6377852B1 (en) * 2000-01-20 2002-04-23 Pacesetter, Inc. Implanatable cardiac stimulation device and method for prolonging atrial refractoriness
US20020062139A1 (en) * 2000-07-13 2002-05-23 Cardiac Pacemakers, Inc. Ventricular conduction delay trending system and method
US6408210B1 (en) * 2000-01-11 2002-06-18 Pacesetter, Inc. System and method for automatic atrial capture detection and atrial pacing threshold determination
US6522922B1 (en) * 2000-07-13 2003-02-18 Cardiac Pacemakers, Inc. Method and apparatus for breaking pacemaker mediated bradycardia
US6553258B2 (en) * 2000-12-26 2003-04-22 Cardiac Pacemakers, Inc. System and method for managing refractory periods in a cardiac rhythm management device with biventricular sensing

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363325A (en) * 1981-01-19 1982-12-14 Medtronic, Inc. Mode adaptive pacer
US4412541A (en) * 1981-04-10 1983-11-01 Max Schaldach Cardiac pacemaker
US4452248A (en) * 1981-10-13 1984-06-05 Keller Jr J Walter Bidirectional pacemaker
US5042497A (en) * 1990-01-30 1991-08-27 Cardiac Pacemakers, Inc. Arrhythmia prediction and prevention for implanted devices
US5133350A (en) * 1991-01-31 1992-07-28 Medtronic, Inc. Mode switching pacemaker
US5247930A (en) * 1992-02-04 1993-09-28 Vitatron Medical, B.V. Dual chamber pacing system with dynamic physiological tracking and method of timing delivered stimulus for optimized synchronous pacing
US5340361A (en) * 1992-11-13 1994-08-23 Siemens Pacesetter, Inc. Implantable pacemaker having adaptive AV interval adoptively shortened to assure ventricular pacing
US5403356A (en) * 1993-04-28 1995-04-04 Medtronic, Inc. Method and apparatus for prevention of atrial tachy arrhythmias
US5514161A (en) * 1994-04-05 1996-05-07 Ela Medical S.A. Methods and apparatus for controlling atrial stimulation in a double atrial triple chamber cardiac pacemaker
US5674251A (en) * 1994-04-21 1997-10-07 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US5716383A (en) * 1996-02-28 1998-02-10 Medtronic, Inc. Dual chamber pacing system and method with continual adjustment of the AV escape interval so as to maintain optimized ventricular pacing for treating cardiomyopathy
US5683429A (en) * 1996-04-30 1997-11-04 Medtronic, Inc. Method and apparatus for cardiac pacing to prevent atrial fibrillation
US5713929A (en) * 1996-05-03 1998-02-03 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using ratchet up and decay modes of operation
US5782887A (en) * 1997-03-26 1998-07-21 Vitatron Medical, B.V. Pacemaker system with PAC tracking based on QT data
US6122545A (en) * 1998-04-28 2000-09-19 Medtronic, Inc. Multiple channel sequential cardiac pacing method
US5978709A (en) * 1998-06-16 1999-11-02 Vitatron Medical, B.V. Pacemaker system with improved techniques for preventing and suppressing atrial arrhythmias
US6330477B1 (en) * 1999-04-12 2001-12-11 Medtronic, Inc. Ventricular synchronized atrial pacing mode of implantable cardioverter/defibrillator
US6292694B1 (en) * 1999-06-22 2001-09-18 Pacesetter, Inc. Implantable medical device having atrial tachyarrhythmia prevention therapy
US6408210B1 (en) * 2000-01-11 2002-06-18 Pacesetter, Inc. System and method for automatic atrial capture detection and atrial pacing threshold determination
US6377852B1 (en) * 2000-01-20 2002-04-23 Pacesetter, Inc. Implanatable cardiac stimulation device and method for prolonging atrial refractoriness
US20020062139A1 (en) * 2000-07-13 2002-05-23 Cardiac Pacemakers, Inc. Ventricular conduction delay trending system and method
US6522922B1 (en) * 2000-07-13 2003-02-18 Cardiac Pacemakers, Inc. Method and apparatus for breaking pacemaker mediated bradycardia
US6553258B2 (en) * 2000-12-26 2003-04-22 Cardiac Pacemakers, Inc. System and method for managing refractory periods in a cardiac rhythm management device with biventricular sensing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260409A (en) * 2018-12-06 2021-08-13 美敦力公司 Method and apparatus for establishing parameters for cardiac event detection
WO2023226600A1 (en) * 2022-05-26 2023-11-30 丹源医学科技(杭州)有限公司 Pacing device for preventing occurrence of atrial fibrillation following premature atrial contraction

Also Published As

Publication number Publication date
US6957104B2 (en) 2005-10-18

Similar Documents

Publication Publication Date Title
US5105810A (en) Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker with means for minimizing bradycardia support pacing voltages
US7065405B2 (en) Stress reduction pacing mode for arrhythmia prevention
US7515959B2 (en) Delivery of CRT therapy during AT/AF termination
US7123959B2 (en) Method and apparatus for preventing cardiac arrhythmias with endovascular stimulation
US8249703B2 (en) Apparatus and method for ventricular rate regularization
US6510343B2 (en) Methods and apparatus for tachycardia rate hysteresis for dual-chamber cardiac stimulators
US20020120298A1 (en) Apparatus and method for ventricular rate regularization
CA2514306A1 (en) Synchronized atrial anti-tachy pacing system and method
US7142915B2 (en) Apparatus and method for ventricular rate regularization
CA2508178A1 (en) Apparatus and method using atp return cycle length for arrhythmia discrimination
EP2355894B1 (en) Overlapping pacing and tachyarrhythmia detection zones
US7164944B1 (en) Analgesic therapy for ICD patients
US6957104B2 (en) Ventricular pacing for prevention of atrial fibrillation
US7050852B2 (en) Pacemaker mode switching based upon atrial conduction time
US6731981B1 (en) Heart stimulator for administering antithrombus therapy
US8644924B2 (en) Preferential mechanical unloading during anti-tachycardia pacing
US9084899B2 (en) Active implantable medical device having antitachycardia atrial and antibradycardia ventricular pacing
EP1347802B1 (en) Apparatus for ventricular rate regularization

Legal Events

Date Code Title Description
AS Assignment

Owner name: CARDIAC PACEMAKERS, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WAGNER, DARRELL O.;REEL/FRAME:012794/0012

Effective date: 20020222

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20131018